Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04284813
Other study ID # 2020P000220
Secondary ID 1K23DA050808-01
Status Completed
Phase N/A
First received
Last updated
Start date September 24, 2020
Est. completion date July 7, 2022

Study information

Verified date September 2022
Source Mclean Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to develop and evaluate an intervention that adapts Community Reinforcement and Family Training (CRAFT) for families experiencing first episode psychosis and substance use delivered via telemedicine (video conferencing). The intervention aims to improve treatment engagement and reduce distress, and it will be delivered via telemedicine (CRAFT-FT). To assess feasibility of the intervention, family members will complete the sessions and provide feedback to refine the treatment manual. Data on client relatives with psychosis will be collected for preliminary assessment purposes. Client relatives will not complete the research study intervention.


Recruitment information / eligibility

Status Completed
Enrollment 29
Est. completion date July 7, 2022
Est. primary completion date August 25, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Ages 18-70. - Having a relative who: 1. Is a patient with early course psychosis (DSM-5 schizophrenia, schizoaffective disorder, schizophreniform, psychosis not otherwise specified (NOS), delusional disorder, brief psychotic disorder, major depression with psychosis, and bipolar disorder with psychosis) with first onset in the past 6 years, and 2. Uses tobacco, alcohol, or cannabis in the past 90 days and/or has no apparent immediate interest in abstinence. - The person(s) who can best describe the client with psychosis. - At least 4 days per month contact with the client. - Access to a computer with internet or mobile phone with video conferencing capabilities. - Ability to provide written informed consent. - Speak and read English. Exclusion Criteria: - DSM-5 moderate or severe substance use disorder in the past year. - Lifetime psychotic disorder. - History of domestic violence with the identified patient (IP). - Psychiatric, cognitive, or medical impairments that would interfere with the ability to follow through with the treatment plan. Inclusion Criteria for Client Relatives: - Ages 18-35. - First episode psychosis (FEP) onset in the past 6 years with a DSM-5 diagnosis of affective (bipolar disorder or major depressive disorder with psychotic features) or non-affective psychosis (schizophrenia spectrum disorder). a. Used tobacco, alcohol, or cannabis within the past 90 days and/or has no apparent immediate interest in abstinence. - Ability to provide written informed consent. - Speak/read English Exclusion Criteria: - N/A

Study Design


Related Conditions & MeSH terms

  • Alcohol
  • Alcohol Use Disorder
  • Alcoholism
  • Bipolar Disorder
  • Cannabis
  • Cigarette Smoking
  • Disease
  • Family
  • Marijuana
  • Mental Disorder
  • Mental Disorders
  • Nicotine Use Disorder
  • Psychosis
  • Psychotic Disorders
  • Schizoaffective Disorder
  • Schizophrenia
  • Substance Use
  • Substance Use Disorders
  • Substance-Related Disorders
  • Tobacco Use
  • Tobacco Use Disorder

Intervention

Behavioral:
CRAFT-FT
CRAFT-FT will be delivered via telemedicine. Topics include building motivation, self-care, communication, understanding patterns of behavior, positive reinforcement, and negative consequences. The intervention will be tailored to families of individuals experiencing psychosis and substance use who are enrolled in first episode psychosis outpatient services. Participants will be asked to completed assessments at pre-treatment, mid-treatment (approximately week 3), post-treatment, and a follow-up assessment approximately 3 month post-treatment.

Locations

Country Name City State
United States McLean Hospital Belmont Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Mclean Hospital National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Meyers RJ, Miller WR, Hill DE, Tonigan JS. Community reinforcement and family training (CRAFT): engaging unmotivated drug users in treatment. J Subst Abuse. 1998;10(3):291-308. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Sessions Completed Percentage of sessions completed during the intervention Post-intervention, approximately Week 6-8
Secondary Mean Session Satisfaction Rating Participants will report weekly satisfaction ratings following each session on the Session Survey. Ratings will range from 1 (poor) to 5 (excellent) for overall experience and convenience. Up to 8 weeks
Secondary Percentage of Participant Preference for In-person, Telemedicine, or Both Session Formats Percentage of participant preference for in-person, telemedicine, or both sessions formats as assessed categorically during the Treatment Satisfaction Interview. Up to 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A